High Court rules that Evotec can buy Cyprotex
13th Dec 2016 11:58
(ShareCast News) - The High Court on Tuesday sanctioned the scheme of arrangement for German drug discovery company Evotec to buy AIM-listed biosciences firm Cyprotex. The court ruled that Frankfurt-listed Evotec could buy the entire issued, and soon to be issued, share capital of Cyprotex by way of
Read moreInvestment boosts revenue and profits at Cyprotex
2nd Aug 2016 13:32
(ShareCast News) - Contract research organisation Cyprotex posted its interim results for the half year to 30 June on Tuesday, with revenues up 26% to £8.73m from £6.93m a year ago. The AIM-traded firm's gross margins were 77.5%, up from 76.8%, with operating profit up significantly to £1.49m from £
Read moreCyprotex unveils new 3D liver model
31st Mar 2016 15:22
(ShareCast News) - Cyprotex was touting its solution to the problem of detecting hepatotoxic potential on Thursday, announcing the launch of a new advanced 3D liver model. The AIM-traded specialist ADME-Tox and Bioscience Contract Research Organisation (CRO) described hepatotoxicity as a major cause
Read moreCyprotex expects full year results to be ahead of expectations
23rd Oct 2015 09:52
(ShareCast News) - Preclinical discovery and development contract researcher Cyprotex said trading had been ahead of expectations in the first nine months of the year. The London-listed group said its financial performance in the three quarters to September had outpaced its own forecast, largely tha
Read moreCyprotex launches new Biosciences division
16th Jul 2015 09:24
(ShareCast News) - Cyprotex has launched a new Biosciences division, which will run alongside its ADME-Tox business. The divisions will offer customers access to Cyprotex's 2D and 3D cell-based efficacy screening, which assesses the therapeutic or biological effects of new molecules. The venture is
Read moreCyprotex posts operating loss for first time in 7 years after contract delays in the US
15th Apr 2015 16:08
Drug research group Cyprotex reported an operating loss in 2014 for the first time in 7 years. Despite a 18.4% increase in revenues to £11.57m during the period, the company posted an operating loss of £3.75m due to investments. In 2013, the company posted a profit of £0.6m. Losses before tax more
Read moreCEO and CFO of Eland Oil & Gas show faith in company's future
4th Jun 2014 16:03
The Chief Executive Officer (CEO) and Chief Financial Officer (CFO) of AIM-listed Eland Oil & Gas have purchased a total of 100,000 shares. The largest deal was made by CEO Leslie Blair, who bought 80,000 shares at 109.30p each for a total spend of £87,440. CFO George Maxwell spent a more modest
Read moreCyprotex acquires fellow research organisation
2nd Jan 2014 09:29
AIM-listed Cyprotex, a contract research organisation, has acquired CeeTox, a division of North American Science Associates. CeeTox, which was acquired for an initial £0.63m, specialises in the provision of in vitro toxicological assays and screening data, principally to the cosmetic and personal
Read moreCyprotex extends ties with Pfizer
30th Oct 2012 11:14
Cyprotex, the pharmaceuticals company specialising in the adverse effects of chemicals on living organisms, has signed a collaborative research agreement with US pharmaceuticals giant Pfizer. The two parties will evaluate, further develop, and improve several of Cyprotex's proprietary offerings in
Read moreSmall caps round-up: Cyprotex, Noble Investments, Accumuli
16th Oct 2012 10:52
Cyprotex rose over three per cent after it said it had signed a licensing agreement with Sigma Life Science. Cyprotex will add Sigma's CompoZr Zinc Finger Nuclease technology to its screening services in an agreement that marks the first non-exclusive licence granted by Sigma for the technology. N
Read moreSmall caps round-up: Symphony Environmental Tech, Cyprotex, Autoclenz...
22nd Mar 2012 12:25
Symphony Environmental Technology, a specialist in advanced plastics technologies, has signed a 20-year exclusive distribution agreement for its d2w plastic technology covering the People's Republic of China, its first ever exclusive distribution agreement for China. Cyprotex, a pre-clinical absorp
Read moreLondon close: Footsie finishes above 6,000
24th Dec 2010 12:55
A late spurt by Footsie in the truncated afternoon trading session did the headline writers a favour and pushed the blue-chip index above the 6,000 level. Trading volumes were low, and corporate news was as thin as the veneer of snow still covering large parts of Britain. Struggling sportswear r
Read moreLondon open: JJB backers rally round
24th Dec 2010 08:37
Trading is every bit as quiet as might be expected on the day before Christmas, with the blue-chip index marginally easier, disappointing those hoping for a move above the 6,000 level. Struggling sportswear retailer JJB Sports has done its best to inject a bit of excitement into proceedings with de
Read moreSmall caps: Media Corp upbeat, Cyprotex on track, Westmount to return 45p...
24th Dec 2010 07:28
Media Corp has seen the best start to a year ever for its online advertising arm, Eyeconomy, with the company describing business as "exceptionally strong". Advertising bookings are a record since the 2011 financial year started in October, Media Corp added. Purple Lounge, Media Corp's online gami
Read moreSmall caps round-up: Mears, BowLeven, Telecom Plus...
1st Oct 2010 11:56
Social housing repairs and maintenance group, Mears, has paid £2.7m for Jackson Lloyd (JL), which mends houses in the North West. JL has an order book in excess of £80m and Mears expects the purchase to be earnings enhancing by the end of next year. Oil explorer Bowleven has agreed a revised optio
Read more